Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
25-Jun-2019
Kazia presents to Gold Coast Investment Showcase
24-Jun-2019
Kazia June Newsletter
20-May-2019
Kazia's GDC-0084 joins Alliance trial in brain cancer
9-May-2019
BNYM substantial shareholder notice
8-May-2019
Becoming a substantial holder
6-May-2019
Top-line safety data from Kazia's GDC-0084 phase II study
5-Apr-2019
Appendix 3Y James Garner
3-Apr-2019
Amended Appendix 3Y Iain Ross
3-Apr-2019
Appendix 3Y Iain Ross
1-Apr-2019
Kazia presents Cantrixil Phase I data at AACR
Previous
1
2
3
4
5
6
Next
